Related Experiment Video

Updated: Jun 24, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Molecular imaging to select cancer therapy and evaluate treatment response

D A Mankoff1

  • 1Seattle Cancer Care Alliance and University of Washington, Seattle, WA 98102, USA. dam@u.washington.edu

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|March 19, 2009
PubMed

Insights

Molecular imaging offers a non-invasive way to track biological processes, aiding in cancer drug development and treatment. This technology helps in early drug testing, clinical trials, and personalized cancer therapy selection.

Area of Science:

  • Oncology
  • Radiology
  • Pharmacology

Background:

  • Molecular imaging enables non-invasive, quantitative assessment of in vivo biological processes.
  • Its application is growing in drug development and clinical cancer practice.

Purpose of the Study:

  • To review the emerging applications of molecular imaging in cancer drug testing and treatment.
  • To highlight the role of imaging in various stages of cancer drug trials and clinical practice.

Main Methods:

  • Review of current literature on molecular imaging in oncology.
  • Discussion of imaging applications in early drug testing, Phase II/III trials, and clinical practice.
  • Analysis of imaging's role in selecting cancer therapy and measuring treatment response.

Main Results:

  • Molecular imaging can guide cancer drug trials from early testing to late-stage clinical evaluation.
  • It aids in selecting therapies by measuring target expression and resistance factors.
  • Imaging assesses early pharmacodynamic changes and treatment response.

Conclusions:

  • Molecular imaging is a valuable tool for cancer drug development and clinical decision-making.
  • Standardization and reproducible quantitative analysis are crucial for widespread adoption.
  • Further integration of molecular imaging promises to enhance personalized cancer care.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET